Article thumbnail

Peptide receptor radionuclide therapy as a potential tool for neoadjuvant therapy in patients with inoperable neuroendocrine tumours (NETs)

By Anna Sowa-Staszczak, Dorota Pach, Robert Chrzan, Małgorzata Trofimiuk, Agnieszka Stefańska, Monika Tomaszuk, Maciej Kołodziej, Renata Mikołajczak, Dariusz Pawlak and Alicja Hubalewska-Dydejczyk
Topics: Original Article
Publisher: Springer-Verlag
OAI identifier: oai:pubmedcentral.nih.gov:3151371
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. Chromogranin A—biological function and clinical utility in neuro endocrine tumor disease.
  2. (2004). Clinical usefulness of 99mTcEDDA/HYNIC-TOC scintigraphy in oncological diagnostics: a pilot study. Cancer Biother Radiopharm
  3. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol 2004;15:966–73.
  4. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.
  5. (2008). Design and endpoints of clinical trials in hepatocellular carcinoma.
  6. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 2008;9:61–72.
  7. Neoadjuvant peptide receptor radionuclide therapy for an inoperable neuroendocrine pancreatic tumor.
  8. New guidelines to evaluate the response to treatment in solid tumors.
  9. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
  10. Staged surgery with neoadjuvant 90Y-DOTATOC therapy for down-sizing synchronous bilobular hepatic metastases from a neuroendocrine pancreatic tumor. Langenbecks Arch Surg 2010;395:185–92.
  11. (2011). Successful neoadjuvant therapy with trastuzumab, paclitaxel and epirubicin for an elderly patient with inflammatory breast cancer. Anticancer Res 2010;30:581–5. PMID 20332474. Eur J Nucl Med Mol Imaging